Financial reports
ARS
2023 FY
Annual report to shareholders
26 Apr 24
10-K
2023 FY
Annual report
29 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
10-K
2022 FY
Annual report
29 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
Current reports
8-K
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
28 Mar 24
8-K
Other Events
12 Feb 24
8-K
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
9 Nov 23
8-K
Company announces Phase 2 part of the EBO-301 trial is now fully enrolled with 80 patients; Topline Phase 2 trial results expected in summer 2024
13 Sep 23
8-K
Departure of Directors or Certain Officers
7 Sep 23
8-K
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock
16 Aug 23
8-K
AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
10 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
8-K
AN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
11 May 23
8-K
AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
29 Mar 23
Registration and prospectus
S-8
Registration of securities for employees
29 Mar 24
424B5
Prospectus supplement for primary offering
16 Aug 23
424B5
Prospectus supplement for primary offering
14 Apr 23
S-3
Shelf registration
6 Apr 23
S-8
Registration of securities for employees
29 Mar 23
S-8
Registration of securities for employees
28 Mar 22
424B4
Prospectus supplement with pricing info
25 Mar 22
S-1MEF
Registration of additional securities for an S-1
24 Mar 22
8-A12B
Registration of securities on exchange
22 Mar 22
S-1/A
IPO registration (amended)
21 Mar 22
Other
EFFECT
Notice of effectiveness
14 Apr 23
CORRESP
Correspondence with SEC
11 Apr 23
UPLOAD
Letter from SEC
10 Apr 23
EFFECT
Notice of effectiveness
25 Mar 22
CERT
Certification of approval for exchange listing
24 Mar 22
SEC STAFF
SEC staff action: Order
24 Mar 22
CORRESP
Correspondence with SEC
22 Mar 22
CORRESP
Correspondence with SEC
22 Mar 22
SEC STAFF
SEC staff action: Order
10 Mar 22
UPLOAD
Letter from SEC
3 Dec 21
Ownership
SC 13G
Frazier Life Sciences Public Fund, L.P.
10 Apr 24
4/A
Paul Eckburg
29 Mar 24
4/A
Lucy Day
29 Mar 24
4/A
Joshua M Eizen
29 Mar 24
4/A
Kevin Michael Krause
29 Mar 24
4/A
Sanjay Chanda
29 Mar 24
4/A
Eric Easom
29 Mar 24
4
Lucy Day
18 Mar 24
4
Joshua M Eizen
18 Mar 24
4
Kevin Michael Krause
18 Mar 24